This is a single arm, open label and non-randomized clinical study with two parts.~In Part A, 6 subjects with advanced solid tumors will be enrolled to assess the safety and explore maximum tolerated dose(MTD) or recommended dose of Neo-T.~Depending on results in Part A, the study may proceed to Part B, where 15 subjects with advanced solid tumors will be enrolled to evaluate the effect of Neo-T.
The primary objective of this study is to evaluate the safety of Neo-T in the treatment of advanced solid tumors.~The secondary objective of this study is to evaluate preliminarily the effect of Neo-T in the treatment of advanced solid tumors.